Dexcom (DXCM): analysis and statistics
Return, volatility, Sharpe ratio and risk for Dexcom, a component of both the S&P 500 and the Nasdaq 100 in the Health Care. Data as of 2026-10-29.
| Last close price | $78.62 |
| Sector (GICS) | Health Care |
| Annualized return (3.0 yr) | -4.18% |
| Total return over period | -11.95% |
| Annualized volatility | 46.53% |
| Period volatility | 80.38% |
| Period T-bill | 12.40% |
| Sharpe ratio | -0.30 |
| Sortino ratio | -0.39 |
| Max drawdown | -60.95% |
| CVaR 95% (avg. loss, worst 5% of days) | -6.72% |
| Correlation with the S&P 500 | 0.27 |
| Period range | $54.84 – $140.45 |
| Trading days analyzed | 752 |
Over the last 3.0 years, Dexcom (DXCM) has posted an annualized return of -4.18% with annual volatility of 46.53%, a negative Sharpe ratio: over this period it did not beat the risk-free Treasury rate. Its worst stretch (max drawdown from a peak) was -60.95%. Its correlation with the S&P 500 is 0.27, which means it moves fairly independently of the index, useful for diversification.
These are historical, realized metrics, not projections: they describe how the stock behaved, not how it will behave going forward. To see how DXCM would fit inside an optimized portfolio alongside other stocks, try the optimizer.
Optimize a portfolio with DXCM →
Other Health Care stocks
Is it part of the S&P 500?
Yes, Dexcom (DXCM) is of both the S&P 500 and the Nasdaq 100.
What is the Sharpe ratio? · How to optimize an investment portfolio